External Validation of the International IgA Nephropathy Prediction Tool in Older Adult Patients

IF 3.5 3区 医学 Q2 GERIATRICS & GERONTOLOGY
Qiuyue Zhang, Qi Zhang, Zhi-juan Duan, Pu Chen, Jing-jing Chen, Ming-xv Li, Jing-jie Zhang, Yan-hong Huo, Wu-xing Zhang, Chen Yang, Yu Zhang, Xiangmei Chen, G. Cai
{"title":"External Validation of the International IgA Nephropathy Prediction Tool in Older Adult Patients","authors":"Qiuyue Zhang, Qi Zhang, Zhi-juan Duan, Pu Chen, Jing-jing Chen, Ming-xv Li, Jing-jie Zhang, Yan-hong Huo, Wu-xing Zhang, Chen Yang, Yu Zhang, Xiangmei Chen, G. Cai","doi":"10.2147/cia.s455115","DOIUrl":null,"url":null,"abstract":"Purpose: The International IgA Nephropathy Prediction Tool (IIgAN-PT) can predict the risk of End-stage renal disease (ESRD) or estimated glomerular filtration rate (eGFR) decline ≥ 50% for adult IgAN patients. Considering the differential progression between older adult and adult patients, this study aims to externally validate its performance in the older adult cohort. Patients and Methods: We analyzed 165 IgAN patients aged 60 and above from six medical centers, categorizing them by their predicted risk. The primary outcome was a ≥50% reduction in estimated glomerular filtration rate (eGFR) or kidney failure. Evaluation of both models involved concordance statistics (C-statistics), time-dependent receiver operating characteristic (ROC) curves, Kaplan– Meier survival curves, and calibration plots. Comparative reclassification was conducted using net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Results: The study included 165 Chinese patients (median age 64, 60% male), with a median follow-up of 5.1 years. Of these, 21% reached the primary outcome. Both models with or without race demonstrated good discrimination (C-statistics 0.788 and 0.790, respectively). Survival curves for risk groups were well-separated. The full model without race more accurately predicted 5-year risks, whereas the full model with race tended to overestimate risks after 3 years. No significant reclassification improvement was noted in the full model without race (NRI 0.09, 95% CI: −0.27 to 0.34; IDI 0.003, 95% CI: −0.009 to 0.019). Conclusion: : Both models exhibited excellent discrimination among older adult IgAN patients. The full model without race demonstrated superior calibration in predicting the 5-year risk.","PeriodicalId":48841,"journal":{"name":"Clinical Interventions in Aging","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Interventions in Aging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/cia.s455115","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: The International IgA Nephropathy Prediction Tool (IIgAN-PT) can predict the risk of End-stage renal disease (ESRD) or estimated glomerular filtration rate (eGFR) decline ≥ 50% for adult IgAN patients. Considering the differential progression between older adult and adult patients, this study aims to externally validate its performance in the older adult cohort. Patients and Methods: We analyzed 165 IgAN patients aged 60 and above from six medical centers, categorizing them by their predicted risk. The primary outcome was a ≥50% reduction in estimated glomerular filtration rate (eGFR) or kidney failure. Evaluation of both models involved concordance statistics (C-statistics), time-dependent receiver operating characteristic (ROC) curves, Kaplan– Meier survival curves, and calibration plots. Comparative reclassification was conducted using net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Results: The study included 165 Chinese patients (median age 64, 60% male), with a median follow-up of 5.1 years. Of these, 21% reached the primary outcome. Both models with or without race demonstrated good discrimination (C-statistics 0.788 and 0.790, respectively). Survival curves for risk groups were well-separated. The full model without race more accurately predicted 5-year risks, whereas the full model with race tended to overestimate risks after 3 years. No significant reclassification improvement was noted in the full model without race (NRI 0.09, 95% CI: −0.27 to 0.34; IDI 0.003, 95% CI: −0.009 to 0.019). Conclusion: : Both models exhibited excellent discrimination among older adult IgAN patients. The full model without race demonstrated superior calibration in predicting the 5-year risk.
国际 IgA 肾病预测工具在老年患者中的外部验证
目的:国际 IgA 肾病预测工具(IIgAN-PT)可以预测成年 IgAN 患者罹患终末期肾病(ESRD)或估计肾小球滤过率(eGFR)下降≥50% 的风险。考虑到老年患者和成年患者的病情进展存在差异,本研究旨在从外部验证其在老年组群中的性能。患者和方法:我们分析了来自六个医疗中心的 165 名 60 岁及以上的 IgAN 患者,并根据其预测风险进行了分类。主要结果是估计肾小球滤过率(eGFR)下降≥50%或肾衰竭。对两种模型的评估包括一致性统计(C 统计)、时间依赖性接收者操作特征曲线(ROC)、卡普兰-梅耶生存曲线和校准图。使用净再分类改进(NRI)和综合辨别改进(IDI)进行比较再分类。研究结果研究共纳入 165 名中国患者(中位年龄 64 岁,60% 为男性),中位随访时间为 5.1 年。其中 21% 的患者达到了主要结果。包含或不包含种族的两个模型均显示出良好的区分度(C 统计量分别为 0.788 和 0.790)。风险组的生存曲线分离良好。不含种族的完整模型能更准确地预测 5 年的风险,而含种族的完整模型则倾向于高估 3 年后的风险。不含种族的完整模型在重新分类方面没有明显改善(NRI 0.09,95% CI:-0.27 至 0.34;IDI 0.003,95% CI:-0.009 至 0.019)。结论::两个模型在老年 IgAN 患者中都表现出了极好的区分度。不含种族的完整模型在预测 5 年风险方面表现出更优越的校准能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Interventions in Aging
Clinical Interventions in Aging GERIATRICS & GERONTOLOGY-
CiteScore
6.80
自引率
2.80%
发文量
193
审稿时长
6-12 weeks
期刊介绍: Clinical Interventions in Aging, is an online, peer reviewed, open access journal focusing on concise rapid reporting of original research and reviews in aging. Special attention will be given to papers reporting on actual or potential clinical applications leading to improved prevention or treatment of disease or a greater understanding of pathological processes that result from maladaptive changes in the body associated with aging. This journal is directed at a wide array of scientists, engineers, pharmacists, pharmacologists and clinical specialists wishing to maintain an up to date knowledge of this exciting and emerging field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信